A Pilot Study to Evaluate for the Abscopal Effect of Durvalumab (Anti-PD-L1) in Combination With Definitive Radiation Therapy in Solitary Bone Plasmacytoma With Limited Clonal Bone Marrow Plasmacytosis
Phase of Trial: Phase I
Latest Information Update: 06 Aug 2017
At a glance
- Drugs Durvalumab (Primary)
- Indications Plasmacytoma
- Focus Therapeutic Use
- 27 Jul 2017 Status changed from not yet recruiting to recruiting.
- 07 Jul 2017 Planned initiation date changed from 1 Jun 2017 to 1 Jul 2017.
- 27 Jun 2017 New trial record